lyophilized human recombinant interferon-beta 1a FP-1201

A lyophilized form of recombinant human interferon (IFN) beta-1a (rhIFNb-1a), with potential protective activity. Upon dissolution of lyophilized rhIFNb-1a FP-1201 and intravenous administration, IFNb-1a upregulates the expression of and increases the levels of 5’-nucleotidase (CD73). This induces adenosine monophosphate (AMP) degradation and the production of adenosine. Adenosine acts to enhance endothelial barrier function via adenosine receptor activation and may prevent or reduce the increased vascular leakage that is due to the lack of adenosine. By increasing adenosine, rhIFNb-1a may protect the lining of blood vessels and thereby reduce inflammation. In addition, FP-1201 may prevent cytokine release syndrome (CRS) and immune effector cell associated-neurotoxicity syndrome (ICANS) toxicities in certain patients receiving CAR T-cell therapy. CD73 is abundantly expressed by normal endothelial cells.